Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,319 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Regulatory
500 approval records across 2 jurisdictions, including tumor-agnostic approvals.
| Drug | Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|---|
| Mercaptopurine | US FDA | Acute Lymphoblastic Leukemia | 1 INDICATIONS & USAGE Mercaptopurine tablets is a nucleoside metabolic inhibitor indicated for treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen. | approved | Sep 11, 1953 | openfda |
| Methotrexate | US FDA | Mycosis Fungoides | Treatment of adults with mycosis fungoides | approved | Nov 29, 2022 | openfda |
| Methotrexate | US FDA | Mycosis Fungoides | Treatment of adults with mycosis fungoides | approved | Nov 29, 2022 | openfda |
| Methotrexate | US FDA | Mycosis Fungoides | Treatment of adults with mycosis fungoides | approved | Nov 29, 2022 | openfda |
| Methotrexate | US FDA | Acute Lymphoblastic Leukemia | Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen | approved | Nov 29, 2022 | openfda |
| Methotrexate | US FDA | Non-Hodgkin Lymphoma | Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen | approved | Nov 29, 2022 | openfda |
| Methotrexate | US FDA | Non-Hodgkin Lymphoma | Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen | approved | Nov 29, 2022 | openfda |
| Methotrexate | US FDA | Acute Lymphoblastic Leukemia | Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen | approved | Nov 29, 2022 | openfda |
| Methotrexate | US FDA | Acute Lymphoblastic Leukemia | Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen | approved | Nov 29, 2022 | openfda |
| Methotrexate | US FDA | Acute Lymphoblastic Leukemia | Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen | approved | Nov 29, 2022 | openfda |
| Methotrexate | US FDA | Non-Hodgkin Lymphoma | Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen | approved | Nov 29, 2022 | openfda |
| Methotrexate | US FDA | Mycosis Fungoides | Treatment of adults with mycosis fungoides | approved | Nov 29, 2022 | openfda |
| Methotrexate | US FDA | Non-Hodgkin Lymphoma | Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen | approved | Nov 29, 2022 | openfda |
| Methotrexate | US FDA | Acute Lymphoblastic Leukemia | Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as a component of a combination chemotherapy maintenance regimen | approved | Apr 25, 2017 | openfda |
| Methotrexate | US FDA | Acute Lymphoblastic Leukemia | Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as a component of a combination chemotherapy maintenance regimen | approved | Apr 25, 2017 | openfda |
| Methotrexate | US FDA | Meningeal Leukemia | o Prophylaxis and treatment of adult and pediatric patients with meningeal leukemia. | approved | Aug 10, 1959 | openfda |
| Methotrexate | US FDA | Head and Neck Squamous Cell Carcinoma | o Treatment of adults with squamous cell carcinoma of the head and neck as a single agent. | approved | Aug 10, 1959 | openfda |
| Methotrexate | US FDA | Osteosarcoma | o Treatment of adult and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. | approved | Aug 10, 1959 | openfda |
| Methotrexate | US FDA | Non-Hodgkin Lymphoma | o Treatment of adult and pediatric patients with non-Hodgkin lymphoma. | approved | Aug 10, 1959 | openfda |
| Methotrexate | US FDA | Acute Lymphoblastic Leukemia | The following neoplastic diseases for the: o Treatment of adult and pediatric patients with acute lymphoblastic leukemia as part of a combination chemotherapy regimen. | approved | Aug 10, 1959 | openfda |
| Midostaurin | US FDA | Acute Myeloid Leukemia | Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. | approved | Apr 28, 2017 | openfda |
| Midostaurin | US FDA | Acute Myeloid Leukemia | Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. | approved | Apr 28, 2017 | openfda |
| Mitomycin | US FDA | Non-Muscle Invasive Bladder Carcinoma | ZUSDURI™ is indicated for the treatment of adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). ZUSDURI is an alkylating drug indicated for the treatment of adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). ( 1 ) | approved | Jun 12, 2025 | openfda |
| Mitotane | US FDA | Adrenal Cortical Carcinoma | LYSODREN is indicated for the treatment of patients with inoperable, functional or nonfunctional, adrenocortical carcinoma (ACC). LYSODREN is an adrenal cytotoxic agent indicated for the treatment of patients with inoperable, functional or nonfunctional, adrenocortical carcinoma (ACC). ( 1 ) | approved | Jul 8, 1970 | openfda |
| Mosunetuzumab | US FDA | Follicular Lymphoma | LUNSUMIO is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).accelerated | approved | Dec 22, 2022 | openfda |
| Neratinib | US FDA | HER2-Positive Breast Carcinoma | In combination with capecitabine, for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting. | approved | Jul 17, 2017 | openfda |
| Neratinib | US FDA | HER2-Positive Breast Carcinoma | As a single agent, for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy. | approved | Jul 17, 2017 | openfda |
| Nilotinib | US FDA | Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive | Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib. | approved | May 29, 2026 | openfda |
| Nilotinib | US FDA | Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive | Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib. | approved | Feb 19, 2025 | openfda |
| Nilotinib | US FDA | Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive | Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib. | approved | Nov 7, 2024 | openfda |
| Nilotinib | US FDA | Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive | Pediatric patients greater than or equal to 1 year of age with Ph+ CML-CP and CML-AP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy. | approved | Oct 29, 2007 | openfda |
| Nilotinib | US FDA | Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive | Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib. | approved | Oct 29, 2007 | openfda |
| Nivolumab | US FDA | Esophageal Squamous Cell Carcinoma | adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). | approved | Dec 22, 2014 | openfda |
| Nivolumab | US FDA | Esophageal Squamous Cell Carcinoma | adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). | approved | Dec 22, 2014 | openfda |
| Nivolumab | US FDA | Lung Non-Small Cell Carcinoma | adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. | approved | Dec 22, 2014 | openfda |
| Nivolumab | US FDA | Lung Non-Small Cell Carcinoma | Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. | approved | Dec 22, 2014 | openfda |
| Nivolumab | US FDA | Urothelial Carcinoma | adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. | approved | Dec 22, 2014 | openfda |
| Nivolumab | US FDA | Head and Neck Squamous Cell Carcinoma | autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. | approved | Dec 22, 2014 | openfda |
| Nivolumab | US FDA | Classic Hodgkin Lymphoma | Classical Hodgkin Lymphoma (cHL) • adult and pediatric (12 years and older) patients with previously untreated, Stage III or IV classical Hodgkin lymphoma in combination with doxorubicin, vinblastine, and dacarbazine (AVD). | approved | Dec 22, 2014 | openfda |
| Nivolumab | US FDA | Lung Non-Small Cell Carcinoma | adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. | approved | Dec 22, 2014 | openfda |
| Nivolumab | US FDA | Pleural Malignant Mesothelioma | Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. | approved | Dec 22, 2014 | openfda |
| Nivolumab | US FDA | Renal Cell Carcinoma | Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. | approved | Dec 22, 2014 | openfda |
| Nivolumab | US FDA | Lung Non-Small Cell Carcinoma | adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. | approved | Dec 22, 2014 | openfda |
| Nivolumab | US FDA | Renal Cell Carcinoma | adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. | approved | Dec 22, 2014 | openfda |
| Nivolumab | US FDA | Renal Cell Carcinoma | adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. | approved | Dec 22, 2014 | openfda |
| Nivolumab | US FDA | dMMR Colorectal Carcinoma | Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. | approved | Dec 22, 2014 | openfda |
| Nivolumab | US FDA | Urothelial Carcinoma | Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. | approved | Dec 22, 2014 | openfda |
| Nivolumab | US FDA | Urothelial Carcinoma | adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. | approved | Dec 22, 2014 | openfda |
| Nivolumab | US FDA | Esophageal Squamous Cell Carcinoma | adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. | approved | Dec 22, 2014 | openfda |
| Nivolumab | US FDA | Classic Hodgkin Lymphoma | adult patients with classical Hodgkin lymphoma that has relapsed or progressed after: | approved | Dec 22, 2014 | openfda |
Data updated 17 hours agoSource updated unknown
Curated evidence
Counts of CIViC evidence items mentioning each therapy for this entity or its descendants. Presence here is not an approval.
| Therapy | Evidence items (count) | Sensitivity / response | Resistance |
|---|---|---|---|
| Dasatinib | 280 | 157 | 123 |
| Imatinib | 241 | 134 | 107 |
| Erlotinib | 234 | 154 | 80 |
| Crizotinib | 207 | 112 | 95 |
| Vemurafenib | 201 | 102 | 98 |
| Gefitinib | 157 | 131 | 26 |
| Sunitinib | 144 | 82 | 61 |
| Afatinib | 112 | 105 | 7 |
| Trametinib | 108 | 94 | 14 |
| Imatinib Mesylate | 97 | 19 | 78 |
| Dabrafenib | 96 | 65 | 31 |
| Bosutinib | 90 | 31 | 59 |
| Sorafenib |
Regulatory status is jurisdiction-specific and changes over time. This page is not treatment guidance.
| 80 |
| 58 |
| 22 |
| Trastuzumab | 75 | 50 | 25 |
| Ponatinib | 59 | 48 | 11 |
| Axitinib | 56 | 16 | 40 |
| Osimertinib | 56 | 42 | 14 |
| Nilotinib | 55 | 20 | 35 |
| Olaparib | 51 | 49 | 2 |
| Selumetinib | 50 | 40 | 10 |
| Cisplatin | 46 | 32 | 13 |
| Lapatinib | 41 | 29 | 12 |
| Entrectinib | 40 | 38 | 2 |
| Erdafitinib | 40 | 38 | 2 |
| Cetuximab | 38 | 31 | 6 |
| Pembrolizumab | 38 | 28 | 10 |
| Chemotherapy | 37 | 34 | 3 |
| Venetoclax | 37 | 4 | 33 |
| Larotrectinib | 36 | 34 | 2 |
| Midostaurin | 33 | 28 | 4 |
| Palbociclib | 33 | 30 | 3 |
| Doxorubicin | 32 | 2 | 30 |
| Ceritinib | 31 | 24 | 7 |
| Gemcitabine | 31 | 21 | 9 |
| Mercaptopurine | 31 | 2 | 28 |
| Everolimus | 30 | 25 | 4 |
| Thioguanine | 29 | 0 | 28 |
| Vismodegib | 29 | 5 | 24 |
| Futibatinib | 28 | 26 | 2 |
| Infigratinib | 26 | 23 | 3 |
| Carboplatin | 25 | 22 | 3 |
| Selpercatinib | 25 | 19 | 6 |
| Alectinib | 24 | 16 | 8 |
| Melphalan | 24 | 0 | 24 |
| Trastuzumab Deruxtecan | 23 | 23 | 0 |
| Atezolizumab | 22 | 20 | 2 |
| Crenolanib | 22 | 21 | 1 |
| Regorafenib Anhydrous | 22 | 19 | 3 |
| BRAF Inhibitor | 21 | 21 | 0 |
| Quizartinib | 21 | 13 | 7 |
| Dactolisib | 20 | 12 | 8 |
| Gilteritinib | 20 | 17 | 3 |
| Lorlatinib | 20 | 16 | 4 |
| Temozolomide | 20 | 17 | 3 |
| Docetaxel | 19 | 13 | 6 |
| Paclitaxel | 19 | 12 | 6 |
| Cobimetinib | 18 | 18 | 0 |
| Cytarabine | 17 | 5 | 12 |
| Neratinib | 17 | 17 | 0 |
| Nivolumab | 17 | 14 | 3 |
| Trastuzumab Emtansine | 17 | 8 | 9 |
| Bevacizumab | 16 | 14 | 2 |
| Cabozantinib | 16 | 15 | 1 |
| Ivosidenib | 16 | 16 | 0 |
| PI103 | 16 | 16 | 0 |
| Binimetinib | 15 | 15 | 0 |
| Capmatinib | 15 | 13 | 1 |
| Dacomitinib | 15 | 14 | 1 |
| Daunorubicin | 15 | 4 | 11 |
| Lestaurtinib | 15 | 14 | 1 |
| Pazopanib | 15 | 14 | 1 |
| Pemetrexed | 15 | 10 | 5 |
| Regorafenib | 15 | 9 | 6 |
| Mitogen-Activated Protein Kinase Kinase Inhibitor | 14 | 13 | 1 |
| Sirolimus | 14 | 14 | 0 |
| Tepotinib | 14 | 14 | 0 |
| Tretinoin | 14 | 8 | 6 |
| Immune Checkpoint Inhibitor | 13 | 10 | 2 |
| Pexidartinib | 13 | 5 | 8 |
| Pictilisib | 13 | 13 | 0 |
| Sotorasib | 13 | 13 | 0 |
| Talazoparib | 13 | 13 | 0 |
| Tazemetostat | 13 | 13 | 0 |
| Pertuzumab | 12 | 12 | 0 |
| Platinum Compound | 12 | 11 | 1 |
| Ruxolitinib | 12 | 12 | 0 |
| Belvarafenib | 11 | 8 | 3 |
| Ibrutinib | 11 | 5 | 6 |
| Methotrexate | 11 | 2 | 9 |
| Prednisone | 11 | 11 | 0 |
| Revumenib | 11 | 4 | 7 |
| Brigatinib | 10 | 9 | 1 |
| Durvalumab | 10 | 9 | 1 |
| PD173074 | 10 | 9 | 1 |
| Asparaginase | 9 | 0 | 9 |
| Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | 9 | 7 | 2 |
| Fluorouracil | 9 | 8 | 1 |
| Mirdametinib | 9 | 7 | 2 |
| Etoposide | 8 | 6 | 2 |
| Fexagratinib | 8 | 7 | 1 |
| Vandetanib | 8 | 7 | 1 |
| ALK Inhibitor TAE684 | 7 | 5 | 2 |
| Dovitinib | 7 | 7 | 0 |
| Enzalutamide | 7 | 7 | 0 |
| Ipilimumab | 7 | 6 | 1 |
| Sunvozertinib | 7 | 7 | 0 |
| VTP-50469 | 7 | 0 | 7 |
| Azacitidine | 6 | 6 | 0 |
| Capecitabine | 6 | 5 | 1 |
| Capivasertib | 6 | 6 | 0 |
| Dabrafenib/Trametinib Regimen | 6 | 6 | 0 |
| Foretinib | 6 | 5 | 1 |
| MEK Inhibitor CI-1040 | 6 | 6 | 0 |
| Pacritinib | 6 | 6 | 0 |
| Panitumumab | 6 | 4 | 2 |
| Pemigatinib | 6 | 5 | 1 |
| PLX4720 | 6 | 1 | 4 |
| Radiation Therapy | 6 | 4 | 2 |
| Rucaparib | 6 | 6 | 0 |
| Taselisib | 6 | 5 | 1 |
| Adavosertib | 5 | 5 | 0 |
| Akt Inhibitor MK2206 | 5 | 5 | 0 |
| Alpelisib | 5 | 4 | 1 |
| Amivantamab | 5 | 5 | 0 |
| Arsenic Trioxide | 5 | 2 | 3 |
| Encorafenib | 5 | 5 | 0 |
| GSK126 | 5 | 5 | 0 |
| JQ1 | 5 | 5 | 0 |
| MTOR Inhibitor | 5 | 5 | 0 |
| Niraparib | 5 | 5 | 0 |
| Pan-RAF/MEK Molecular Glue NST-628 | 5 | 5 | 0 |
| PD1 Inhibitor | 5 | 4 | 1 |
| R3Mab | 5 | 4 | 1 |
| Rociletinib | 5 | 4 | 1 |
| Sapanisertib | 5 | 5 | 0 |
| SU11274 | 5 | 5 | 0 |
| Abemaciclib | 4 | 4 | 0 |
| Arabinosylguanine | 4 | 1 | 3 |
| Asciminib | 4 | 4 | 0 |
| Dordaviprone | 4 | 4 | 0 |
| Enasidenib | 4 | 4 | 0 |
| FLT3 Tyrosine Kinase Inhibitor TTT-3002 | 4 | 4 | 0 |
| Icotinib | 4 | 3 | 1 |
| Ipilimumab/Nivolumab Regimen | 4 | 4 | 0 |
| Irinotecan | 4 | 4 | 0 |
| Linifanib | 4 | 4 | 0 |
| MEK Inhibitor RO4987655 | 4 | 0 | 4 |
| Nelarabine | 4 | 1 | 3 |
| Olutasidenib | 4 | 4 | 0 |
| Panobinostat | 4 | 4 | 0 |
| PI3Ka/Di | 4 | 3 | 1 |
| Pralsetinib | 4 | 1 | 3 |
| Repotrectinib | 4 | 4 | 0 |
| Ribociclib | 4 | 3 | 1 |
| Uprosertib | 4 | 4 | 0 |
| Vincristine | 4 | 3 | 1 |
| Vinorelbine | 4 | 4 | 0 |
| Vistusertib | 4 | 4 | 0 |
| Vorasidenib | 4 | 4 | 0 |
| AG1295 | 3 | 3 | 0 |
| Alisertib | 3 | 3 | 0 |
| Alvespimycin | 3 | 3 | 0 |
| Anti-CTLA-4 Monoclonal Antibody | 3 | 2 | 1 |
| Anti-PD1 Monoclonal Antibody | 3 | 2 | 1 |
| Anti-PD-L1 Monoclonal Antibody | 3 | 1 | 2 |
| Anti-VEGF Monoclonal Antibody | 3 | 2 | 1 |
| Apitolisib | 3 | 3 | 0 |
| ARS-1620 | 3 | 3 | 0 |
| Avapritinib | 3 | 3 | 0 |
| Avelumab | 3 | 2 | 1 |
| AZD-4547 | 3 | 3 | 0 |
| Bafetinib | 3 | 1 | 2 |
| Buparlisib | 3 | 3 | 0 |
| Cisplatin/Pembrolizumab/Pemetrexed Regimen | 3 | 0 | 3 |
| Deguelin | 3 | 3 | 0 |
| Dinaciclib | 3 | 2 | 1 |
| EAP Protocol | 3 | 3 | 0 |
| Ensartinib | 3 | 3 | 0 |
| FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074 | 3 | 3 | 0 |
| FLT3/ABL/Aurora Kinase Inhibitor KW-2449 | 3 | 1 | 2 |
| Fulvestrant | 3 | 2 | 1 |
| JQEZ5 | 3 | 3 | 0 |
| KW2449 | 3 | 3 | 0 |
| Lazertinib | 3 | 3 | 0 |
| Lenvatinib | 3 | 2 | 1 |
| Letetresgene Autoleucel | 3 | 3 | 0 |
| Mitomycin | 3 | 2 | 1 |
| Oxaliplatin | 3 | 1 | 2 |
| PI-103 | 3 | 3 | 0 |
| PI3Kbeta Inhibitor AZD8186 | 3 | 3 | 0 |
| PI3K/BET Inhibitor LY294002 | 3 | 3 | 0 |
| Poziotinib | 3 | 3 | 0 |
| Prednisolone | 3 | 0 | 3 |
| R406 | 3 | 3 | 0 |
| Ramucirumab | 3 | 2 | 1 |
| Refametinib | 3 | 2 | 1 |
| RG7112 | 3 | 2 | 1 |
| Sonidegib | 3 | 2 | 1 |
| SU5614 | 3 | 0 | 3 |
| Tanespimycin | 3 | 3 | 0 |
| Temsirolimus | 3 | 3 | 0 |
| Tipifarnib | 3 | 3 | 0 |
| Vorinostat | 3 | 3 | 0 |
| Zongertinib | 3 | 3 | 0 |
| Adagrasib | 2 | 2 | 0 |
| Adjuvant Chemotherapy | 2 | 2 | 0 |
| AGI-5198 | 2 | 2 | 0 |
| AGS324 | 2 | 2 | 0 |
| ALK2 Inhibitor LDN-193189 | 2 | 2 | 0 |
| Anti-CD33 | 2 | 2 | 0 |
| Anti-PD-1 Monoclonal Antibody MEDI0680 | 2 | 2 | 0 |
| Aspirin | 2 | 2 | 0 |
| Aumolertinib | 2 | 1 | 1 |
| Bazedoxifene | 2 | 1 | 1 |
| Birabresib | 2 | 2 | 0 |
| Bortezomib | 2 | 2 | 0 |
| B-Raf/VEGFR-2 Inhibitor RAF265 | 2 | 2 | 0 |
| Camonsertib | 2 | 2 | 0 |
| Canertinib | 2 | 2 | 0 |
| Carboplatin/Paclitaxel Regimen | 2 | 2 | 0 |
| Carboplatin/Pemetrexed Regimen | 2 | 2 | 0 |
| Celecoxib | 2 | 2 | 0 |
| Checkpoint Kinase Inhibitor AZD7762 | 2 | 2 | 0 |
| CTX-712 | 2 | 2 | 0 |
| Decitabine | 2 | 2 | 0 |
| Derazantinib | 2 | 2 | 0 |
| Durvalumab/Tremelimumab Regimen | 2 | 2 | 0 |
| EPZ011989 | 2 | 2 | 0 |
| Firmonertinib | 2 | 2 | 0 |
| FLT3 Inhibitor FF-10101 Succinate | 2 | 2 | 0 |
| Hematopoietic Cell Transplantation | 2 | 2 | 0 |
| Imlunestrant Regimen | 2 | 2 | 0 |
| Immunotherapy | 2 | 2 | 0 |
| Irbesartan | 2 | 2 | 0 |
| JQ-1 | 2 | 2 | 0 |
| JSI-124 | 2 | 2 | 0 |
| KRAS G12D Inhibitor HRS-4642 | 2 | 2 | 0 |
| L19IL2 | 2 | 2 | 0 |
| Leucovorin | 2 | 2 | 0 |
| Lometrexol | 2 | 2 | 0 |
| Lomustine | 2 | 2 | 0 |
| Lunresertib | 2 | 2 | 0 |
| Masitinib | 2 | 1 | 1 |
| Meloxicam | 2 | 2 | 0 |
| Metformin | 2 | 2 | 0 |
| Mobocertinib | 2 | 2 | 0 |
| Motesanib | 2 | 0 | 2 |
| Nab-paclitaxel | 2 | 1 | 1 |
| Nimotuzumab | 2 | 2 | 0 |
| Nirogacestat | 2 | 2 | 0 |
| NSC348884 | 2 | 2 | 0 |
| NSC84167 | 2 | 2 | 0 |
| Omacetaxine Mepesuccinate | 2 | 2 | 0 |
| Palbociclib Regimen | 2 | 2 | 0 |
| Prexasertib | 2 | 2 | 0 |
| R-CHOP Regimen | 2 | 1 | 1 |
| Retaspimycin Hydrochloride | 2 | 2 | 0 |
| Ripretinib | 2 | 2 | 0 |
| Rovalpituzumab Tesirine | 2 | 2 | 0 |
| Sacituzumab Govitecan | 2 | 0 | 2 |
| Salinomycin | 2 | 2 | 0 |
| Savolitinib | 2 | 1 | 1 |
| Setidegrasib | 2 | 2 | 0 |
| Sevabertinib | 2 | 2 | 0 |
| Sintilimab | 2 | 2 | 0 |
| Sotrastaurin Acetate | 2 | 2 | 0 |
| Sulindac | 2 | 2 | 0 |
| Taletrectinib | 2 | 2 | 0 |
| Tandutinib | 2 | 1 | 1 |
| Tovorafenib | 2 | 2 | 0 |
| Trabectedin | 2 | 2 | 0 |
| Tremelimumab | 2 | 2 | 0 |
| Tyrphostin AG 1296 | 2 | 2 | 0 |
| U0126 | 2 | 0 | 2 |
| Valproic Acid | 2 | 2 | 0 |
| Zenocutuzumab-zbco | 2 | 2 | 0 |
| Ziftomenib | 2 | 2 | 0 |
| Zolbetuximab | 2 | 2 | 0 |
| 2,4-pyrimidinediamine | 1 | 1 | 0 |
| 2-Deoxy-D-glucose | 1 | 1 | 0 |
| 3-Dimensional Conformal Radiation Therapy | 1 | 1 | 0 |
| 4'-(9-acridinylamino)methanesulfon-m-anisidide | 1 | 0 | 1 |
| 5-Fluoro-2-Deoxycytidine | 1 | 1 | 0 |
| 6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)-N-(4-(methylsulfonyl)phenyl)pyridin-2-amine | 1 | 1 | 0 |
| 7-Ethyl-10-Hydroxycamptothecin | 1 | 1 | 0 |
| 9F7-F11 | 1 | 1 | 0 |
| A66 | 1 | 1 | 0 |
| Abemaciclib Regimen | 1 | 1 | 0 |
| Abexinostat | 1 | 1 | 0 |
| Abiraterone | 1 | 1 | 0 |
| Adebrelimab | 1 | 1 | 0 |
| Ado-trastuzumab Emtansine Regimen | 1 | 1 | 0 |
| Alemtuzumab | 1 | 1 | 0 |
| ALK Inhibitor ASP3026 | 1 | 1 | 0 |
| Alvocidib | 1 | 1 | 0 |
| AMG511 | 1 | 1 | 0 |
| Amuvatinib | 1 | 1 | 0 |
| Anthracycline Antineoplastic Antibiotic | 1 | 0 | 1 |
| Anti-CD123 | 1 | 1 | 0 |
| Antigen-specific Cytotoxic T-lymphocyte Therapy | 1 | 1 | 0 |
| Anti-PDL1 Therapy | 1 | 1 | 0 |
| Antisecretory Factor-enriched Egg Yolk Powder Supplement | 1 | 1 | 0 |
| Anti-TIM-3 Monoclonal Antibody | 1 | 1 | 0 |
| Aromatase Inhibitor | 1 | 1 | 0 |
| AS602868 | 1 | 1 | 0 |
| ATR Inhibitor | 1 | 1 | 0 |
| Avutometinib And Defactinib | 1 | 1 | 0 |
| AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M | 1 | 1 | 0 |
| AZ12908010 | 1 | 0 | 1 |
| AZ20 | 1 | 1 | 0 |
| AZ628 | 1 | 1 | 0 |
| AZ909 | 1 | 1 | 0 |
| Azathioprine | 1 | 0 | 0 |
| AZD3463 | 1 | 0 | 1 |
| Barasertib | 1 | 1 | 0 |
| BCR-ABL Inhibitor HS-10382 | 1 | 1 | 0 |
| Befotertinib | 1 | 1 | 0 |
| BET Inhibitor | 1 | 1 | 0 |
| Bevacizumab/Lomustine Regimen | 1 | 1 | 0 |
| Bicalutamide | 1 | 0 | 1 |
| Bimiralisib | 1 | 1 | 0 |
| BMVC-8C3O | 1 | 1 | 0 |
| Bone Marrow Transplantation | 1 | 1 | 0 |
| BPTES | 1 | 1 | 0 |
| C646 | 1 | 1 | 0 |
| Camptothecin | 1 | 1 | 0 |
| Camrelizumab | 1 | 1 | 0 |
| CAPOX Regimen | 1 | 1 | 0 |
| Carboplatin OR Cisplatin | 1 | 0 | 1 |
| Carmustine | 1 | 1 | 0 |
| C-DIM 12 | 1 | 0 | 1 |
| CDK4/6 Inhibition | 1 | 1 | 0 |
| CH6953755 | 1 | 1 | 0 |
| Chemoimmunotherapy | 1 | 0 | 1 |
| Chemoradiotherapy | 1 | 0 | 1 |
| CHMFL-KIT-031 | 1 | 1 | 0 |
| CHZ868 | 1 | 1 | 0 |
| C-Met Inhibitor | 1 | 1 | 0 |
| Copanlisib | 1 | 1 | 0 |
| CTLA-4 Inhibitor | 1 | 1 | 0 |
| Cytoreductive Surgery | 1 | 1 | 0 |
| Dacarbazine | 1 | 1 | 0 |
| Dacomitinib | 1 | 1 | 0 |
| Daromun | 1 | 1 | 0 |
| Datopotamab Deruxtecan | 1 | 1 | 0 |
| Datopotamab Deruxtecan Regimen | 1 | 1 | 0 |
| Dexamethasone | 1 | 1 | 0 |
| Divarasib | 1 | 1 | 0 |
| Donor Lymphocyte Infusion | 1 | 1 | 0 |
| Dostarlimab | 1 | 1 | 0 |
| DS-6501b | 1 | 1 | 0 |
| Durvalumab Regimen | 1 | 1 | 0 |
| DVP Regimen | 1 | 0 | 1 |
| EGFR Tyrosine Kinase Inhibitor Therapy | 1 | 1 | 0 |
| Enzastaurin | 1 | 1 | 0 |
| Eprenetapopt | 1 | 1 | 0 |
| EPZ004777 | 1 | 1 | 0 |
| ERBB3 Inhibitor | 1 | 1 | 0 |
| Eribulin | 1 | 1 | 0 |
| Erlotinib Hydrochloride | 1 | 1 | 0 |
| Fadraciclib | 1 | 1 | 0 |
| Fasudil | 1 | 1 | 0 |
| Fedratinib | 1 | 1 | 0 |
| FGFR4 Inhibitor H3B-6527 | 1 | 1 | 0 |
| Fisogatinib | 1 | 1 | 0 |
| Fludarabine | 1 | 1 | 0 |
| FOLFOX-6 Regimen | 1 | 1 | 0 |
| Galiximab | 1 | 1 | 0 |
| Ganetespib | 1 | 1 | 0 |
| Ganitumab | 1 | 1 | 0 |
| Gemtuzumab Ozogamicin | 1 | 1 | 0 |
| G-Quadruplex Stabilizer BMVC | 1 | 1 | 0 |
| GSK321 | 1 | 1 | 0 |
| Guadecitabine | 1 | 1 | 0 |
| GW-2580 | 1 | 1 | 0 |
| HDAC Inhibitor OBP-801 | 1 | 1 | 0 |
| HDM2 Inhibitor MK-8242 | 1 | 1 | 0 |
| HyperCVAD Regimen | 1 | 1 | 0 |
| Hyperthermic Intraperitoneal Chemotherapy | 1 | 1 | 0 |
| I-BET151 | 1 | 1 | 0 |
| Ibuprofen | 1 | 1 | 0 |
| ICX-101 | 1 | 1 | 0 |
| Idarubicin | 1 | 1 | 0 |
| Idelalisib | 1 | 1 | 0 |
| IMG-2005-5 | 1 | 1 | 0 |
| Iodine I-131 | 1 | 0 | 1 |
| IRAK-1/4 Inhibitor | 1 | 1 | 0 |
| JAK2 Inhibitor AZD1480 | 1 | 1 | 0 |
| JAK Inhibitor I | 1 | 1 | 0 |
| JNJ38877605 | 1 | 0 | 1 |
| JQ1 Compound | 1 | 1 | 0 |
| JW55 | 1 | 1 | 0 |
| K 252a | 1 | 0 | 1 |
| Lenalidomide | 1 | 0 | 1 |
| Linsitinib | 1 | 1 | 0 |
| Luminespib | 1 | 0 | 1 |
| Lumretuzumab | 1 | 1 | 0 |
| Mcl-1 Inhibitor MIK665 | 1 | 1 | 0 |
| MEK-1/MEKK-1 Inhibitor E6201 | 1 | 1 | 0 |
| MEK Inhibitor REC-4881 | 1 | 1 | 0 |
| Menin Inhibitor | 1 | 1 | 0 |
| MET Tyrosine Kinase Inhibitor SGX523 | 1 | 1 | 0 |
| Mocetinostat | 1 | 1 | 0 |
| Molibresib | 1 | 1 | 0 |
| MTOR Kinase Inhibitor AZD8055 | 1 | 1 | 0 |
| MUC1-targeted Peptide GO-203-2C | 1 | 0 | 1 |
| Multi-subtype Natural Human Leukocyte Interferon Alpha | 1 | 0 | 1 |
| MVT Regimen | 1 | 0 | 1 |
| Naquotinib | 1 | 0 | 1 |
| Navtemadlin | 1 | 1 | 0 |
| NCT00137111 | 1 | 1 | 0 |
| Nedaplatin | 1 | 0 | 1 |
| Ningetinib | 1 | 1 | 0 |
| Nintedanib | 1 | 1 | 0 |
| Not Applicable | 1 | 0 | 0 |
| Nutlin-3 | 1 | 1 | 0 |
| NVP-AEW541 | 1 | 1 | 0 |
| NVP-AST487 | 1 | 1 | 0 |
| O6-Benzylguanine | 1 | 1 | 0 |
| OICR-9429 | 1 | 1 | 0 |
| Omipalisib | 1 | 1 | 0 |
| Onalespib | 1 | 1 | 0 |
| Onartuzumab | 1 | 1 | 0 |
| Onatasertib | 1 | 1 | 0 |
| Osimertinib Mesylate | 1 | 1 | 0 |
| Paclitaxel Liposome | 1 | 1 | 0 |
| Palliative Radiation Therapy | 1 | 0 | 1 |
| Pan-AKT Kinase Inhibitor GSK690693 | 1 | 1 | 0 |
| Pan-Mutant-IDH1 Inhibitor Bay-1436032 | 1 | 1 | 0 |
| Patritumab | 1 | 1 | 0 |
| PCV Regimen | 1 | 1 | 0 |
| PD-1 Ligand Inhibitor | 1 | 1 | 0 |
| PD-L1 Inhibitor | 1 | 1 | 0 |
| Peginterferon Alfa-2a | 1 | 1 | 0 |
| Peginterferon Alfa-2b | 1 | 1 | 0 |
| Pembrolizumab/Pemetrexed Regimen | 1 | 1 | 0 |
| Pertuzumab/Trastuzumab Regimen | 1 | 0 | 1 |
| PHA-665752 | 1 | 0 | 1 |
| Pilaralisib | 1 | 1 | 0 |
| Pixantrone | 1 | 0 | 1 |
| Platinum Doublet | 1 | 0 | 1 |
| Pomalidomide | 1 | 0 | 1 |
| Porcupine Inhibitor WNT974 | 1 | 1 | 0 |
| PSI | 1 | 1 | 0 |
| Pyridostatin | 1 | 1 | 0 |
| Pyrotinib | 1 | 1 | 0 |
| Radioactive Iodine | 1 | 1 | 0 |
| Raltitrexed | 1 | 0 | 1 |
| Rilotumumab | 1 | 1 | 0 |
| Rindopepimut | 1 | 1 | 0 |
| RMC-4550 | 1 | 1 | 0 |
| Roflumilast | 1 | 1 | 0 |
| Safusidenib | 1 | 1 | 0 |
| Salirasib | 1 | 1 | 0 |
| Samotolisib | 1 | 1 | 0 |
| SCH772984 | 1 | 1 | 0 |
| Selective Estrogen Receptor Covalent Antagonist H3B-6545 | 1 | 1 | 0 |
| Selinexor | 1 | 0 | 1 |
| Sertraline | 1 | 1 | 0 |
| SHP2 Inhibitor | 1 | 1 | 0 |
| Sorafenib Tosylate | 1 | 1 | 0 |
| Stattic | 1 | 1 | 0 |
| Staurosporine | 1 | 1 | 0 |
| TAK-788 | 1 | 1 | 0 |
| Tamibarotene | 1 | 0 | 1 |
| Tarextumab | 1 | 1 | 0 |
| Tarloxotinib | 1 | 1 | 0 |
| Taxane Compound | 1 | 1 | 0 |
| Teprotumumab | 1 | 1 | 0 |
| Tgx 221 | 1 | 1 | 0 |
| TGX221 | 1 | 1 | 0 |
| Therapeutic Glucocorticoid | 1 | 0 | 1 |
| Tirbanibulin | 1 | 1 | 0 |
| Tisagenlecleucel | 1 | 0 | 1 |
| Tislelizumab | 1 | 1 | 0 |
| Tizaterkib | 1 | 1 | 0 |
| Tofacitinib | 1 | 1 | 0 |
| Toripalimab | 1 | 1 | 0 |
| Tozasertib | 1 | 1 | 0 |
| Trichostatin A | 1 | 1 | 0 |
| Triciribine | 1 | 1 | 0 |
| Tunlametinib | 1 | 1 | 0 |
| Tyrosine Kinase Inhibitor | 1 | 1 | 0 |
| Tyrosine Kinase Inhibitor SU5402 | 1 | 1 | 0 |
| Tyrphostin AG 1295 | 1 | 1 | 0 |
| Tyrphostin AG 1478 | 1 | 1 | 0 |
| UNC1062 | 1 | 1 | 0 |
| UNC1999 | 1 | 1 | 0 |
| UO126 | 1 | 1 | 0 |
| Vatalanib | 1 | 1 | 0 |
| VE-821 | 1 | 1 | 0 |
| Volasertib | 1 | 1 | 0 |
| VTP50469 | 1 | 1 | 0 |
| VTX-11e | 1 | 1 | 0 |
| WHI-P154 | 1 | 1 | 0 |
| WRN Inhibitor HRO761 | 1 | 1 | 0 |
| WRN Inhibitor RO7589831 | 1 | 1 | 0 |
| WZ4002 | 1 | 0 | 1 |
Curated Items are counted regardless of level or direction; see the evidence tab for the detail.